Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss - Wikidata - wikimedia - TriplyDB

Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss

Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss

http://www.wikidata.org/entity/Q34106300

about

Recent advances in the application of metabolomics to Alzheimer's Disease From Molecules to the Clinic: Linking Schizophrenia and Metabolic Syndrome through Sphingolipids Metabolism Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse White matter abnormalities associated with Alzheimer's disease and mild cognitive impairment: a critical review of MRI studies.Is Alzheimer's disease a systemic disease?Dietary and behavioral interventions protect against age related activation of caspase cascades in the canine brain.Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease.Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases Developing novel blood-based biomarkers for Alzheimer's disease Gadd153 and NF-κB crosstalk regulates 27-hydroxycholesterol-induced increase in BACE1 and β-amyloid production in human neuroblastoma SH-SY5Y cells.Emerging biomarkers in cognition.Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?Acid sphingomyelinase gene deficiency ameliorates the hyperhomocysteinemia-induced glomerular injury in mice.Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease.Rapid evaluation of 25 key sphingolipids and phosphosphingolipids in human plasma by LC-MS/MS.Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease Novel advances in shotgun lipidomics for biology and medicine.Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II.Phospholipids and Alzheimer's disease: alterations, mechanisms and potential biomarkers.Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?Robust Diffeomorphic Mapping via Geodesically Controlled Active Shapes.Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer's pathology Peripheral sphingolipids are associated with variation in white matter microstructure in older adults.Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study.Development and validation of LC-MS/MS method for determination of very long acyl chain (C22:0 and C24:0) ceramides in human plasma A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study.Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease.Lipidomics of Alzheimer's disease: current status.Quantitative metabolic profiling of lipid mediators.Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes.Lipidomics of Alzheimer's disease.Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease.A Comparison of Lysosomal Enzymes Expression Levels in Peripheral Blood of Mild- and Severe-Alzheimer's Disease and MCI Patients: Implications for Regenerative Medicine Approaches.Intracellular Cholesterol Trafficking and Impact in Neurodegeneration.Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents.

P2860

Q26828606-8D19C4AA-84C6-4C6B-9BCA-E8C93DBAB9DA Q28067617-7DFEB8C8-99DE-4488-A3F9-CE3E13D5ABB2 Q28547451-E9290B62-EE67-4FFD-9C74-0D5FC2F18B17 Q30363059-D3B12D22-FB26-4E55-9921-6600F908A81C Q30620060-715E5860-4851-4EBE-8C31-9B37D6960A82 Q34019193-289E4877-CB25-4B17-9ADB-B2859CEDE416 Q34023846-5CEF4ABF-DA81-4803-8CC1-A037F1B20D6E Q34223125-5A807DD5-114E-45D6-8CBE-E5DDDD1C548C Q34288447-DFBAE700-3263-47A5-BEAA-AA01FFB25BDD Q34394080-F6BAF39B-3FC9-4F92-972C-C9A7A5E4B201 Q34947624-F3FE3173-4AC7-4817-BC07-F1FAF96080E2 Q35008258-61813269-29A3-4EA5-8A2E-7A83986BFBAA Q35065194-BB13CE8C-7DE6-422A-9FE1-A5A3A227DC97 Q35086073-678D0C53-584F-49BA-8339-4A1B1FE28B8E Q35474438-89123C14-2D42-40C7-AF77-D595A687BCFF Q35555867-541C917D-9B69-4C51-8A46-32E1BFCAF150 Q35753420-5873B603-5075-43DF-97EC-18E81F878EFC Q35833686-87425A46-183E-4105-A4EE-2CEC8B15094B Q35878177-87D03292-CB71-4C75-87B7-567C2DC971D8 Q35997884-B4827171-79C4-4D82-A1A2-4C9FB91EA4A4 Q36149981-4B290F4D-86CF-4823-AC66-86924E11CFE7 Q36590043-C418F90F-BB80-409C-9C41-35291552B095 Q36768801-4DF3DF76-2890-45C1-A6CE-13917F211040 Q36802122-61B7F76C-2C74-4689-BB8E-A94FB7D655D2 Q36855949-E9A2655A-FE5D-4DF1-AEB0-15634C4DAFB7 Q36973077-9B2C456B-E122-4A74-9152-946280971CDF Q37091714-7A77AAFC-3517-4DBD-9DF6-C340DEC478DB Q37155265-200036B5-3053-4A21-9900-0A8F9CCAF12A Q37541514-C58B8574-FBA6-4B9B-9E24-E1D253CB84BB Q37543795-138B5542-A687-4226-97BA-B286FA10B336 Q37550487-BA922C84-C7D7-43D3-9BBC-D8488BDC3FB1 Q37980283-A5337A22-B45F-41D8-8B67-9E066864FC55 Q38119472-CC7222A7-8D9D-47C4-8F75-D033B51206D3 Q38120648-20C446A4-31EF-4D5E-AC5E-9171C920BDAD Q38125769-C275F043-7331-4761-B371-306E0152797B Q38191024-5DA9CAE1-C42C-468F-80F8-5C8E19F14675 Q40444820-0A99284E-1424-473A-952E-3207BCD262F0 Q41574522-4388D15C-4F87-4C72-810D-4FA298E0DE55 Q45305840-D1B4A4E7-E64A-4A35-B554-25874CB48F35 Q46426783-3D5DE57A-A56D-4283-9159-A6800F8BECA7

P2860

Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss

http://www.wikidata.org/entity/Q34106300

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@ast

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@en

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@nl

type

label

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@ast

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@en

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@nl

prefLabel

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@ast

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@en

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@nl

P1433

Q34106300-D46124EF-3646-4412-B158-FA2F41E5708F

P1476

Q34106300-954DB80D-2DBA-496F-85BD-C1B0E1EE4DA0

P2093

Q34106300-0A1E3C27-52C2-4027-BE5E-DC19408F160E

Q34106300-20AC0DB8-5915-4196-9C94-A31E3ED14B1E

Q34106300-2C699BB8-010D-432D-80E8-7380C99AD000

Q34106300-41830C5D-10AB-4AE3-A7FE-E41E56231DDD

Q34106300-6D0259B6-D135-497A-A381-A51B7BB0542D

Q34106300-902ED5AD-C822-49D5-8BD8-90B616A25ED6

Q34106300-9CB3D6A8-5898-473E-9022-F50A30EE7D4A

Q34106300-AB5F0B73-0BAC-4C31-B24C-337074200FC8

Q34106300-BB50DF40-C56F-4DC8-9D59-C22A96F7BF62

P2860

Q34106300-0F2745B1-38C6-49BA-857A-DB564EDE279B

Q34106300-22581AC7-4A92-43D0-AB66-F49F9DB5EE47

Q34106300-268FE3D3-F6B1-4B69-836D-055E7C83925A

Q34106300-2BCDE21F-1B3F-4C30-89E8-14539D8D3955

Q34106300-31F434F6-F774-45DB-A031-D6D38F81E195

Q34106300-32BEEE3B-3757-4F93-9A56-2A09F173ACD7

Q34106300-35DDEBF2-DE4E-45E1-AFDA-6ADD30ED3C1E

Q34106300-5679A717-9DCF-40C5-852A-AC4BBA16916C

Q34106300-578E197A-961D-4DC6-9558-BC72A7F9C0D0

Q34106300-589042A7-D211-450B-833B-D7DC2CC1DBCF

P304

Q34106300-234ACF7E-F1CF-4A0F-9DE6-CB3EC124EECC

P31

Q34106300-AF288160-2D9C-4F5B-9949-CD7E122D3FD9

P356

Q34106300-5C08ADCF-CA41-4FDE-97BD-223B855EC050

P433

Q34106300-A2911C4C-166F-42BE-8CAB-E67659B0B46F

P478

Q34106300-7E8DC21D-858A-4209-947C-96FCE4B3F45A

P50

Q34106300-5F28ECC5-E94A-4861-8D72-3E3ED6FF4D8D

Q34106300-5F7B2BE3-4924-4268-9605-520954F869E4

Q34106300-B236C000-DF1D-4B5D-8F20-40BFD3FEE46F

P577

Q34106300-DC7DD163-8097-45F5-9CD3-8D50B27CEA43

P5875

Q34106300-AEEEE2AA-9355-40A4-B217-F545269F0A33

P698

Q34106300-C5F50979-804B-488D-8B1D-450A8C231FD6

P932

Q34106300-4C845EC6-F597-4AD7-8674-2F7E78796763

P356

J.JALZ.2010.03.014

P1433

Alzheimer's and Dementia

P1476

Plasma ceramides are altered i ...... ne and hippocampal volume loss

@en

P2093

Constantine G Lyketsos

http://www.w3.org/2001/XMLSchema#string

Michael I Miller

http://www.w3.org/2001/XMLSchema#string

Michelle C Carlson

http://www.w3.org/2001/XMLSchema#string

Michelle M Mielke

http://www.w3.org/2001/XMLSchema#string

Norman J Haughey

http://www.w3.org/2001/XMLSchema#string

Richard Carrick

http://www.w3.org/2001/XMLSchema#string

Steven Schech

http://www.w3.org/2001/XMLSchema#string

Timothy Brown

http://www.w3.org/2001/XMLSchema#string

Veera Venkata Ratnam Bandaru

http://www.w3.org/2001/XMLSchema#string

P2860

Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes.

Global prevalence of dementia: a Delphi consensus study

The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.

“Mini-mental state”

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Landmark matching via large deformation diffeomorphisms

Mild cognitive impairment as a diagnostic entity

Deregulation of sphingolipid metabolism in Alzheimer's disease.

Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein

P304

378-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2010.03.014

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46123831

http://www.w3.org/2001/XMLSchema#string

P698

20813340

http://www.w3.org/2001/XMLSchema#string

P932

2933928

http://www.w3.org/2001/XMLSchema#string